Yushi Zhang

List of Publications by Year
in descending order

47	473	686830 13	794141 19
papers	citations	h-index	g-index

56	56	56	750
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2656-2665.	3.3	38
2	Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC. Frontiers in Oncology, 2019, 9, 663.	1.3	32
3	LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 717.	1.3	31
4	Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma. PLoS ONE, 2015, 10, e0115896.	1.1	30
5	Retroperitoneal Laparoscopic Management of Paraganglioma: A Single Institute Experience. PLoS ONE, 2016, 11, e0149433.	1.1	25
6	Primitive Neuroectodermal Tumors of Adrenal Gland. Japanese Journal of Clinical Oncology, 2010, 40, 800-804.	0.6	24
7	Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Orphanet Journal of Rare Diseases, 2018, 13, 43.	1.2	24
8	Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor A. Oncology Reports, 2016, 35, 1778-1786.	1.2	23
9	miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma. Laboratory Investigation, 2018, 98, 856-870.	1.7	20
10	UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma. BMC Cancer, 2019, 19, 1195.	1.1	19
11	Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults. Oncology Letters, 2015, 10, 2865-2870.	0.8	17
12	The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas. International Journal of Endocrinology, 2016, 2016, 1-8.	0.6	17
13	Assessment of Tuberous Sclerosis Complex Associated With Renal Lesions by Targeted Next-generation Sequencing in Mainland China. Urology, 2017, 101, 170.e1-170.e7.	0.5	16
14	Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study. Frontiers in Endocrinology, 2020, 11, 574662.	1.5	14
15	iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma. BioMed Research International, 2015, 2015, 1-6.	0.9	13
16	A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. International Urology and Nephrology, 2020, 52, 437-446.	0.6	13
17	Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using ⁶⁸Ga-Pentixafor. Journal of Nuclear Medicine, 2022, 63, 368-375.	2.8	11
18	CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. International Urology and Nephrology, 2019, 51, 671-676.	0.6	10

#	Article	IF	Citations
19	Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings. Frontiers in Endocrinology, 2021, 12, 663096.	1.5	10
20	Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease. International Journal of Clinical and Experimental Medicine, 2015, 8, 19311-7.	1.3	10
21	Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker. Frontiers in Oncology, 2020, 10, 1507.	1.3	7
22	Transmuscular quadratus lumborum block for postoperative pain and recovery after laparoscopic adrenalectomy: a randomized controlled trial. BMC Anesthesiology, 2021, 21, 274.	0.7	7
23	Genotype-phenotype correlation of patients with tuberous sclerosis complexâ€“associated renal angiomyolipoma: a descriptive study. Human Pathology, 2018, 82, 61-67.	1.1	6
24	Construction and validation of an m6A RNA methylation regulator prognostic model for earlyâ€‘stage clear cell renal cell carcinoma. Oncology Letters, 2022, 24, .	0.8	5
25	Transumbilical laparoendoscopic singleâ€site surgery versus conventional laparoscopy for the resection of retroperitoneal paragangliomas. International Journal of Urology, 2015, 22, 844-849.	0.5	4
26	Clinical and genetic analysis of tuberous sclerosis complexâ€‘associated renal angiomyolipoma in Chinese pedigrees. Oncology Letters, 2017, 14, 7085-7090.	0.8	4
27	Survival analysis of surgically treated renal cell carcinoma: a single Chinese medical center experience from 2002 to 2012. International Urology and Nephrology, 2015, 47, 1327-1333.	0.6	3
28	A Rare Aldosterone-Producing Adenoma Detected by 68Ga-pentixafor PET-CT: A Case Report and Literature Review. Frontiers in Endocrinology, 2019, 10, 810.	1.5	3
29	Clinical significance of phenotyping and karyotyping of detecting circulating tumor cells in renal cell carcinoma using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH). International Urology and Nephrology, 2020, 52, 2281-2287.	0.6	3
30	Analysis of renal lesions in Chinese tuberous sclerosis complex patients with different types of TSC gene mutations. Genetics and Molecular Biology, 2022, 45, .	0.6	3
31	Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma. Cellular Oncology (Dordrecht), 2016, 39, 15-21.	2.1	2
32	The Effects of Different Calcium Channel Blockers on Aldosterone-Producing Adenoma Cells. Frontiers in Endocrinology, 2020, 11, 260.	1.5	2
33	Solitary vaginal paraganglioma with mature sacrococcygeal teratoma: a rare case report. BMC Endocrine Disorders, 2021, 21, 145.	0.9	2
34	High-throughput screening of circRNAs reveals novel mechanisms of tuberous sclerosis complex-related renal angiomyolipoma. Human Genomics, 2021, 15, 43.	1.4	2
35	PTEN inhibitor VOâ€‘OHpic suppresses TSC2â€‘/â€‘ MEFs proliferation by excessively inhibiting autophagy via the PTEN/PRAS40 pathway. Experimental and Therapeutic Medicine, 2020, 19, 3565-3570.	0.8	2
36	Analysis of serum lipid parameters predicting lipid metabolic disorders in TSCâ€AML patients with treatment of mTOR inhibitors. Journal of Clinical Pharmacy and Therapeutics, 2022, , .	0.7	2

#	Article	IF	Citations
37	Papillary renal neoplasm with reverse polarity: A case report. Asian Journal of Surgery, 2022, 45, 2390-2390.	0.2	2
38	Bilateral Adrenal Tumors from Different Histology: Case Report and Literature Review. Cell Biochemistry and Biophysics, 2015, 71, 425-429.	0.9	1
39	Bladder Varices Caused by Portal Hypertension. Cell Biochemistry and Biophysics, 2015, 72, 795-798.	0.9	1
40	Reply. Urology, 2017, 101, 176.	0.5	1
41	High Preoperative Plasma Fibrinogen Independently Predicts a Poor Prognosis in Patients with Nonmetastatic RCC. Journal of Cancer, 2020, 11, 2401-2407.	1.2	1
42	The Small Size and Superficial Location Suggest That Laparoscopic Partial Nephrectomy Is the First Choice for the Treatment of Juxtaglomerular Cell Tumors. Frontiers in Endocrinology, 2021, 12, 646649.	1.5	1
43	Re: Kapoor et al.: Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML) (Urology 2016;89:19-26). Urology, 2017, 100, 255.	0.5	0
44	Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4 cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85â€“90. European Urology, 2017, 71, e141-e142.	0.9	0
45	The Bioinformatics Analysis of Aldosterone-Producing Adenoma and Verification of Differentially Expressed Genes. International Journal of Endocrinology, 2021, 2021, 1-7.	0.6	0
46	Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003. European Urology, 2022, 81, e120.	0.9	0
47	Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145â€“8. European Urology, 2022, 81, e65.	0.9	0